10-Q: Scientific Industries Reports Reduced Losses in Q2 2024 Amidst Strategic Cost-Cutting Measures

Scientific Industries, Inc. reports a reduced loss for the second quarter of 2024, driven by strategic cost reductions and despite a decrease in overall revenue.

Summary

• Scientific Industries, Inc. reported a net loss of $1.28 million for the three months ended June 30, 2024, an improvement compared to the $2.29 million loss in the same period of 2023.
• The company's revenue decreased by 11.2% to $2.65 million in Q2 2024, down from $2.98 million in Q2 2023, primarily due to lower sales in the Benchtop Laboratory Equipment segment.
• The gross profit margin increased to 48.8% in Q2 2024 from 45.3% in Q2 2023, mainly due to improved margins in the Bioprocessing Systems segment.
• Operating expenses decreased significantly, with general and administrative expenses down by 18.3% and selling expenses down by 43.4% due to cost-cutting measures.
• For the six months ended June 30, 2024, the company's net loss was $3.34 million, compared to a $4.66 million loss in the same period of 2023.
• Revenue for the first six months of 2024 was $5.13 million, a decrease of 12.8% from $5.79 million in the first six months of 2023.
• The company's cash and cash equivalents stood at $560,500 as of June 30, 2024, down from $796,100 at the end of 2023.
• The company has an accumulated deficit of $30.82 million as of June 30, 2024, and management has expressed concerns about the company's ability to continue as a going concern without additional capital.

Sentiment

Score: 3

Explanation: The document indicates a challenging financial situation with declining revenue, significant losses, and concerns about the company's ability to continue as a going concern. While cost-cutting measures are positive, the overall outlook is negative.

Positives

• The company's net loss decreased significantly in both the three and six month periods ending June 30, 2024.
• Gross profit margin improved in the second quarter of 2024.
• Operating expenses were significantly reduced due to cost-cutting measures.
• The company successfully raised capital through the issuance of common stock and warrants.
• The company is actively seeking additional capital resources to address its liquidity concerns.

Negatives

• The company experienced a decrease in revenue in both the three and six month periods ending June 30, 2024.
• The company has an accumulated deficit of $30.82 million as of June 30, 2024.
• The company's cash and cash equivalents decreased to $560,500 as of June 30, 2024.
• Management has expressed concerns about the company's ability to continue as a going concern without additional capital.
• Sales of Torbal and VIVD brand products decreased due to new regulations related to pharmacy direct and indirect renumeration fees.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital resources.
• The company's revenue is declining, particularly in the Benchtop Laboratory Equipment segment.
• The company faces challenges in the independent pharmacy market due to new regulations.
• The company has a significant accumulated deficit.
• The company's cash reserves are decreasing.

Future Outlook

The company's management is making plans to secure additional capital resources, which may include capital from management and significant shareholders, as well as third-party equity and/or debt financing. However, there is no assurance that these plans will be successful.

Management Comments

• The company was able to reduce the loss from continuing operations primarily due to decreased expenses resulting from operating cost reductions mostly in the Bioprocessing Systems Operations segment and decreased Corporate expenses compared to the prior year periods.
• The decrease in revenue was driven primarily by lower revenues of Benchtop Laboratory Equipment Operations.
• The increase in gross profit percentage is due primarily to higher gross margin percentage in the Bioprocessing Systems Operations.
• The decrease in general and administrative expenses is primarily due to decreased Corporate expenses related to external professional services and non-cash stock-based compensation expense compared to prior year period.
• The decrease in selling expenses is due primarily to the reduction of sales and marketing employees in conjunction to the strategic operational and product development plan for the Bioprocessing Systems Operations.
• The decrease in research and development expenses is due primarily to the reduction of research and development expenditures related to the VIVID automated pill counter in the Benchtop Laboratory Equipment Operations.

Industry Context

The company's performance is affected by market conditions, including post-COVID destocking and overall market softness for laboratory equipment, particularly in Asia. The company also faces challenges due to new regulations impacting the independent pharmacy market.

Comparison to Industry Standards

• The company's revenue decline is concerning, as many companies in the laboratory equipment and bioprocessing sectors are experiencing growth or stability.
• The reduction in operating expenses is a positive step, but the company's overall financial health remains precarious.
• The company's gross profit margin of 45.5% for the six months ended June 30, 2024 is below the industry average for similar companies, such as Thermo Fisher Scientific (approximately 50%) and Danaher (approximately 55%).
• The company's net loss of $3.34 million for the six months ended June 30, 2024 is significantly worse than the performance of larger, more established competitors in the industry.
• The company's cash position of $560,500 is very low compared to industry standards, where companies typically maintain a much larger cash reserve to fund operations and growth initiatives.

Management Changes

Related Party Transactions

• The company paid $31,300 and $47,300 to Mr. John Nicols, a Director of the Company, for consulting services during the three and six months ended June 30, 2024, respectively.

Stakeholder Impact

• Shareholders are impacted by the company's declining revenue and significant losses.
• Employees are impacted by the reduction in force and salary/compensation waiver program.
• Customers may be impacted by the company's financial instability.
• Suppliers may be impacted by the company's financial instability.
• Creditors may be impacted by the company's financial instability.

Next Steps

• The company will seek additional capital resources to fund its operations.
• The company will continue to implement cost-cutting measures.
• The company will focus on strategic operational and product development plans for the Bioprocessing Systems Operations.

Key Dates

Keywords

financial results, quarterly report, cost reduction, revenue decline, net loss, bioprocessing systems, benchtop laboratory equipment, stock options, capital raise, going concern